Asthma Exacerbation, COPD Exacerbation, Lower Respiratory Disease, Pneumonia
Conditions
Brief summary
Aim is to to demonstrate that the ResAppDx v2.0 algorithms provide an accurate diagnosis of respiratory disease in the study's clinical setting compared to a clinical adjudication committee's (CAC) diagnosis; and to establish a baseline for the resource use and cost of current care pathways for respiratory disease diagnosis in an emergency department. Eligible subjects will be consented/enrolled and their subject reported signs/symptoms of respiratory disease will be recorded in the study electronic case report form (eCRF). The enrolled subject's cough sounds will be captured (5 cough sounds are required) using the ResAppDx v2.0 Investigational Device (ID) software installed on a study smartphone; cough sounds may be voluntary and/or involuntary/spontaneous. As this is an observational study the treating team will be blinded to the ResAppDx v2.0 diagnoses. Additional medical information will be collected from the treating team, from the subject and from the subject's medical record. No follow-up/subsequent visits with the subject will be required by the study. As an efficacy comparator, a clinical adjudication committee (CAC) will determine the final clinical diagnosis using the disease case definitions, eCRF data and the subject's medical record. Information on time and scope of tests and consults ordered by the treating team will be recorded to set a baseline for resource use and cost of current standard of care treatment/assessment procedures. This data will allow future health economics analyses to be performed. The blinded ResAppDx v2.0 diagnoses will be unblinded after database lock and sensitivity and specificity will be calculated for the ResAppDx v2.0 diagnoses compared to agreement with the CAC's final clinical diagnoses.
Interventions
DEVICEResAppDx v.20
Software device measuring cough sounds to aid diagnosis of respiratory diseases
Sponsors
ResApp Health Limited
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Inclusion criteria
* Adolescents and adults aged 12 years and older: 1. Presenting to the study site with current signs or symptoms of rhinorrhea, cough, wheeze, stridor, increased work of breathing, cyanosis, additional auscultatory noises (crepitations), or low oximetry levels. 2. Onset of symptoms must have occurred within 14 days of presenting to the site.
Exclusion criteria
* 1\. Parent or legal guardian is unwilling or unable to sign the study informed consent form. 2\. Adolescent patient who, in the opinion of the investigator, is able to provide assent based on their age, maturity or psychological state is unwilling or unable to sign the study assent form. 3\. Patient requires mechanical ventilatory support (including invasive, CPAP, or BiPAP) or high flow nasal cannula. 4\. Patient has a history of structural airways abnormalities, tracheobronchomalacia, or vocal cord abnormalities (e.g. laryngomalacia, tracheomalacia, or bronchomalacia). 5\. Patient has any medical contraindication to voluntary cough, including the following (only enroll if coughing spontaneously): a. Severe respiratory distress b. History of pneumothorax c. Eye, chest, or abdominal surgery within 3 months of presenting to the site 6. Hemoptysis within 1 month of presenting to the site. 7. Patient is too medically unstable to participate in study at the discretion of the treating clinician. 8\. Patient has a tracheostomy present and/or has a tracheostomy tube placed. 9. Patient is unable to provide at least 5 coughs (voluntary and/or spontaneous).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of ResAppDx v2.0 when compared to clinical adjudication panel | 6 months | Efficacy will be compared to the diagnosis formed by consensus of the clinical adjudication committee and evaluated using sensitivity and specificity of ResAppDx v2.0 algorithms (Index Test) to diagnose and rule out the following conditions: * Asthma exacerbation; * COPD exacerbation; * Lower respiratory tract disease (LRTD); and * Pneumonia (including lower respiratory tract infection). |
Countries
United Kingdom
Outcome results
None listed